Exploring the effects of Factor Xa inhibitors on thrombin generation in people with haemophilia

• Published in: Thrombosis research 2024-05, Vol.237, p.148-153
• Main Authors: Dix, Caroline, McFadyen, James D., Tran, Huyen A.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antibodies, Bispecific - pharmacology; Antibodies, Bispecific - therapeutic use; Antibodies, Monoclonal, Humanized - therapeutic use; Anticoagulants; Cardiovascular disease; Factor Xa Inhibitors - pharmacology; Factor Xa Inhibitors - therapeutic use; Female; Haemophilia; Hemophilia A - blood; Hemophilia A - drug therapy; Humans; Male; Middle Aged; Pyrazoles - therapeutic use; Pyridones; Rivaroxaban - pharmacology; Rivaroxaban - therapeutic use; Thrombin - metabolism; Thrombin generation; Young Adult
• ISSN: 0049-3848; 1879-2472
• DOI: 10.1016/j.thromres.2024.03.031

Optimal management of cardiovascular disease (CVD) in people with haemophilia (PWH) is a growing issue, given the continuing improvement in life expectancy among PWH. The evolving treatment paradigms targeting higher trough levels and the advent of non-factor replacement therapies (NFRT) means much of the ‘protection’ PWH were thought to have against CVD may be lost. There is a paucity of evidence regarding the safety of using anticoagulants in PWH. We designed a study assessing the thrombin generation (TG) of PWH of different severities and treatments, compared to non-haemophilia patients receiving a Factor Xa (FXa) inhibitor (apixaban or rivaroxaban), healthy controls, and assessing TG parameters of adding FXa inhibitor to the plasma of PWH receiving emicizumab prophylaxis. In total, 40 patients were included. TG was initiated with 5pM tissue factor (TF) using the calibrated automated thrombinoscope. Compared to those with mild haemophilia, patients receiving a FXa inhibitor had higher endogenous thrombin potential (ETP) (1278.42 vs 1831.36) and velocity index (40.71 vs 112.56), but both had a similar peak height (154.0 vs 262.63) and time to peak (both 5.83). People with severe haemophilia receiving emicizumab had significantly improved TG parameters compared to those not receiving emicizumab – ETP 1678.11 vs 809.96 and peak height 233.8 vs 92.05; however, when FXa inhibitor was added their TG parameters deteriorated to the severe haemophilia range (ETP 1179.60 and peak height 103.05). TG may provide additional useful information regarding the use of anticoagulants in PWH. •People with haemophilia now have a life expectancy approaching the general population and may develop cardiovascular disease•Little is known about the use and safety of anticoagulants in people with haemophilia•Thrombin generation (TG) assays may be able to provide additional information regarding the use of anticoagulants in this setting.•People with mild haemophilia (factor level 5-20%) have similar tTG profiles to non-haemophilia patients receiving FXa inhibitors•People with severe haemophilia receiving emicizumab have TG parameters closer to normal, but when FXa inhibitor is added in vitro, these parameters return to the severe haemophilia range